huMNC2-CAR T cells

huMNC2-CAR T cells are autologous chimeric antigen receptor (CAR) T cell therapies targeting MUC1*, a cancer-specific cleavage product of the MUC1 transmembrane glycoprotein. MUC1* is expressed on the surface of over 75% of solid tumor cells, including up to 93% of human breast cancers, but not on normal tissue. The huMNC2 single-chain variable fragment (scFv) used in these CARs binds specifically to MUC1*, enabling tumor-selective targeting. There are two main variants: huMNC2-CAR44, which utilizes a 41BB co-stimulatory domain, and huMNC2-CAR22, which incorporates a CD28 co-stimulatory domain and "1XX" tyrosine-to-phenylalanine mutations in the CD3ζ signaling domain. These modifications in huMNC2-CAR22 are intended to enhance CAR T cell persistence, reduce exhaustion, and improve cytotoxicity against low antigen-expressing tumor cells. Early-phase clinical trials are ongoing in patients with metastatic breast cancer, with preclinical and early clinical data showing promising safety and antitumor activity in solid tumors[1][2][3][4][5][6][8][10].

Other names

huMNC2 CAR T cellshuMNC-2 CAR T cellshuMNC 2 CAR T cellsMUC1*-CAR T cells